Wells Fargo Analyst Sees Potential in Argenx SE's (ARGX) Vyvgart, Increases PT to $1,317

Argenx SE (NASDAQ:ARGX) is one of the 11 Best Stocks to Buy for Investment.

On January 20, TheFly reported that Wells Fargo increased the price target on Argenx SE (NASDAQ:ARGX) from $1,264 to $1,317, keeping an Overweight rating on the shares.

Derek Archila from Wells Fargo raised the price target on ARGX following its strong outlook on Argenx’s Vyvgart, according to TheFly. Archila has raised the 2026-2030 Vyvgart outlook by 5-15%. Vyvgart is an antibody used to treat severe autoimmune diseases, such as myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.

The analyst believes Argenx SE’s FY2026 consensus estimate of $5.6 billion is too low given the growth trajectory. Archila expects the company to generate approximately $6.5 billion, considering single-digit quarter-over-quarter growth in Q1 FY2026 and low double-digital quarter-over-quarter growth between Q2 and Q4. Wall Street’s consensus estimate of $1.18 billion for Q1 indicates a growth of almost 65.79% from a year ago.

Over the past six months, Argenx SE’s shares have soared by over 45% as of January 27. Out of 28 analysts covering ARGX, 86% rank the stock as a Buy. ARGX has a median price target of $1,007.86, representing an upside of 16.80%.

Argenx SE (NASDAQ:ARGX) is a commercial-stage biopharma company. Argenx is developing therapies to treat autoimmune diseases.

While we acknowledge the potential of ARGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best New Penny Stocks to Invest In and 13 Best Gold Mining Companies to Invest In Now.

Disclosure: None. This article is originally published at Insider Monkey.